![](https://cdn.benzinga.com/files/images/story/2024/09/09/ELVN.png?width=1200&height=800&fit=crop)
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
HC Wainwright initiated coverage on Enliven Therapeutics, Inc. ELVN and noted the company as an emerging biotech company developing next-gen precision-oriented small molecules for solid and liquid tumor indications. Enliven’s pipeline includes: ELVN-001— a …